Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vismodegib Maintenance in Ovarian Cancer
NCT00739661Phase 2Completed
- Sponsor
- Genentech
- Start
- Dec 2008
- Primary completion
- Nov 2010
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in ovarian cancer, primary peritoneal carcinoma (PPC) and fallopian tube carcinoma (PFTC) comparing Vismodegib with Placebo (2 arms). Primary endpoint: Progression-free Survival at 100 weeks. Started Dec 2008; status: completed.
02
Drugs
vismodegib
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube carcinoma (PFTC)
Beyond the preview
Go deeper on NCT00739661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00739661.